VEGFR-1/Flt-1 (D3) (glycosylated), (Monomer), (Soluble) (Active) Protein

Produktnummer ABIN1589607

Produktdetails

Target: VEGFR-1/Flt-1 (D3)

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: glycosylated, Monomer, Soluble

Spezies: Human

Quelle: Insektenzellen

Sequenz: SKLKDPELSL KGTQHIMQAG QTLHLQCRGE AAHKWSLPEM VSKESERLSI TKSACGRNGK QFCSTLTLNT AQANHTGFYS CKYLAVPTSK KKETESAIYI FISDTGRPFV EMYSEIPEII HMTEGRELVI PCRVTSPNIT VTLKKFPLDT LIPDGKRIIW DSRKGFIISN ATYKEIGLLT CEATVNGHLY KTNYLTHRQT NTIIDVQIST PRPVKLLRGH TLVLNCTATT PLNTRVQMTW SYPDEKNKRA SVRRRIDQSN SHANIFYSVL TIDKMQNKDK GLYTCRVRSG PSFKSVNTSV HIYDKAFITV KHRKQQVLET VAGKRSY

Produktmerkmale: Length (AA): 327
Chromosomal location: 13q12
The activity of sVEGFR-1(D3) was determined by its ability to inhibit the VEGF-A-induced proliferation of HUVECs.

Reinheit: > 90 % by SDS-PAGE. Visualized by silver stain

Anwendungsinformationen

Kommentare:

Soluble Receptors

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: The lyophilized sVEGFR-1(D3) is soluble in water and most aqueous buffers and should be reconstituted in PBS to a concentration not lower than 100 ng/mL.

Buffer: PBS

Lagerung: -20 °C/-80 °C

Informationen zur Lagerung: Lyophilized samples are stable for greater than six months at -20 °C to -70 °C. Reconstituted sVEGFR-1(D3) should be stored in working aliquots at -70 °C.

Haltbarkeit: 6 months

Antigendetails

Target: VEGFR-1/Flt-1 (D3)

Hintergrund: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVE supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.
Synonyms: soluble vascular endothelial growth factor receptor-1, soluble FLT1, soluble VEGFR-1

Molekulargewicht: 45.0 kDa

NCBI Accession: NM_001159920, NP_001153392

UniProt: P17948